What is the recommended treatment for Congenital Adrenal Hyperplasia (CAH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Congenital Adrenal Hyperplasia (CAH)

Patients with CAH require lifelong glucocorticoid replacement with hydrocortisone as the first-line agent at 15-25 mg daily in divided doses, combined with mineralocorticoid replacement using fludrocortisone 0.1-0.2 mg daily for salt-losing forms. 1, 2

Glucocorticoid Replacement

First-Line Therapy

  • Hydrocortisone (HC) is the preferred glucocorticoid for CAH treatment in both children and adults 1, 3
  • Standard adult dosing: 15-25 mg per day in 2-3 divided doses 1
  • Dosing schedule: First dose upon awakening, last dose 4-6 hours before bedtime 1
  • Available tablet strengths: 20 mg, 10 mg, and 2.5 mg 1

Alternative Glucocorticoid Options

  • Cortisone acetate (CA) can be used as an alternative to HC, though it has delayed onset requiring hepatic activation 1
  • CA dosing: 25 mg and 5 mg tablets, taken in divided doses 1
  • Dexamethasone may be used in adults with doses ranging from 0.0625 to 0.875 mg/day (mean 0.4 mg/day), though this is considerably lower than traditionally recommended 4
  • Prednisone is FDA-approved for CAH but is not preferred over HC in children 5

Critical Dosing Principle

Avoid dexamethasone in routine pediatric CAH management as hydrocortisone better mimics physiologic cortisol replacement and allows more precise dose titration 3, 6

Mineralocorticoid Replacement

Standard Fludrocortisone Dosing

  • Recommended dose: 0.1-0.2 mg daily as a single morning dose for salt-losing CAH 7, 2
  • FDA-approved dosing for salt-losing adrenogenital syndrome: 0.1-0.2 mg daily 2
  • Children and younger adults may require higher doses (up to 500 μg daily) 8

Dose Adjustment Algorithm

Increase fludrocortisone when: 8, 7

  • Hyponatremia (low sodium) is present
  • Hyperkalemia (high potassium) develops
  • Orthostatic hypotension occurs despite adequate sodium intake
  • Persistent salt cravings continue

Decrease fludrocortisone (but never stop completely) when: 8, 7

  • Hypertension develops
  • Peripheral edema appears
  • Supine hypertension is documented

Monitoring Parameters

  • Blood pressure in supine and standing positions 8, 7
  • Serum sodium and potassium levels 8, 7
  • Body weight and clinical symptoms (salt cravings, lightheadedness, edema) 8
  • Annual review minimum, with electrolytes checked at each visit 8, 7

Stress Dosing and Acute Management

Illness and Fever

  • Double the oral glucocorticoid dose for 24 hours during febrile illness, then return to normal dose 1
  • This recommendation is supported even with low-quality evidence due to life-threatening consequences of under-treatment 1

Adrenal Crisis Management

Immediate treatment protocol: 1

  • Hydrocortisone 100 mg IV bolus immediately
  • Follow with 100-300 mg/day as continuous infusion or 100 mg IV/IM every 6 hours
  • Rapid isotonic saline infusion: 1 L over first hour, then 3-4 L total over 24-48 hours 1
  • Do not delay treatment for diagnostic testing 1

Surgical Stress Dosing

  • Major surgery: 100 mg hydrocortisone IM just before procedure, continue stress dosing until oral intake resumes 1, 7
  • Minor procedures: Usually not required, but give extra 20 mg HC if symptoms develop 1
  • Dental procedures: Extra morning dose 1 hour prior 1

Monitoring Treatment Adequacy

Clinical Assessment (Primary Method)

Plasma ACTH and serum cortisol are NOT useful for dose adjustment 1

Signs of over-replacement: 1

  • Weight gain
  • Insomnia
  • Peripheral edema

Signs of under-replacement: 1

  • Lethargy and fatigue
  • Nausea and poor appetite
  • Weight loss
  • Increased or uneven pigmentation
  • Salt cravings 8

Biochemical Monitoring

  • Target 17-hydroxyprogesterone normalization in adults 4
  • Serum electrolytes (sodium, potassium) for mineralocorticoid adequacy 8, 7
  • Growth velocity and bone age in children 6, 9

Critical Safety Measures

Patient Education Requirements

  • All patients must wear medical alert identification and carry a steroid emergency card 1, 8
  • Training in intramuscular HC self-administration for emergencies 1
  • Education on stress dose increases during illness, injury, or surgery 1

Common Pitfalls to Avoid

  • Never stop fludrocortisone abruptly - can trigger life-threatening adrenal crisis with hypotension, hyponatremia, and hyperkalemia 8
  • Never completely discontinue fludrocortisone for hypertension - reduce dose instead 8, 7
  • Under-replacement with fludrocortisone is common and predisposes to recurrent adrenal crises 8
  • Delays in emergency HC administration can be fatal 1

Drug Interactions Requiring Attention

  • CYP3A4 inducers/inhibitors affect HC clearance and may require dose adjustment 1
  • Avoid: Diuretics, acetazolamide, NSAIDs, potassium-containing salt substitutes, licorice, and grapefruit juice 8, 7
  • Drospirenone-containing contraceptives may require higher fludrocortisone doses 8, 7

Dietary Recommendations

  • Liberal salt and salty food intake encouraged 8, 7
  • Avoid "healthy" potassium-containing salt substitutes 8

Special Populations

Pregnancy

  • Small fludrocortisone dose adjustments may be needed, particularly in third trimester due to progesterone's anti-mineralocorticoid effects 8, 7

Non-Classical CAH

  • Glucocorticoid therapy recommended only for: 9
    • Inappropriately early or rapidly progressing pubarche
    • Accelerated bone age progression in children
    • Overt virilization in adolescents
  • Stress doses of HC recommended for major surgery, trauma, or childbirth only if suboptimal cortisol response to ACTH stimulation test 9

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a clinical practice audit.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2003

Research

Congenital Adrenal Hyperplasia.

Pediatrics in review, 2024

Guideline

Fludrocortisone Dosing in Congenital Adrenal Hyperplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Adjusting Fludrocortisone Dose in Adult Adrenal Insufficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.